The New York Entrepreneur

Cognition Therapeutics announces positive results from trial of oral treatment for mild-to-moderate Alzheimer’s disease

Read Time:9 Second

The Purchase, N.Y.-based company found patients treated with its experimental pill CT1812 for six months showed a consistent trend in cognitive improvement across all measures and cognitive scales.

About Post Author

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
Previous post You’ll know AI has taken over when we no longer value money
Next post McDonald’s earnings include a triple miss, but the stock gains ground